Jeffrey Royce, MD
Family Medicine · Rockford, ILNPI 1619910635
Payments from drug & device makers
Across 1,316 payments — averaging $676.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$556K
- Amgen$133K
- Lilly USA, LLC$75K
- Biohaven Pharmaceutical Holding Company Ltd.$42K
- Biohaven Pharmaceuticals, Inc.$38K
- Teva Pharmaceuticals USA, Inc.$19K
- plus $27K from 24 others
What the payments were for
- Consulting fees$101,47211%
- Speaking & faculty fees$706,93579%
- Travel & lodging$54,8066%
- Food & beverage$26,7023%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 567 | $555,946 |
| Amgen | 182 | $133,325 |
| Lilly USA, LLC | 148 | $74,726 |
| Biohaven Pharmaceutical Holding Company Ltd. | 50 | $42,143 |
| Biohaven Pharmaceuticals, Inc. | 50 | $37,508 |
| Teva Pharmaceuticals USA, Inc. | 102 | $19,440 |
| Impel Pharmaceuticals Inc. | 36 | $14,052 |
| Lundbeck LLC | 61 | $5,198 |
| Impel Pharmaceuticals LLC | 6 | $3,791 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $1,310 |
| Pfizer | 26 | $636 |
| Supernus Pharmaceuticals, Inc. | 31 | $519 |
| Axsome Therapeutics, Inc. | 6 | $345 |
| Tonix Medicines, Inc. | 4 | $222 |
| Novartis | 9 | $192 |
| Merck | 8 | $137 |
| Upsher-smith Laboratories LLC | 5 | $125 |
| Bausch Health US, LLC | 3 | $60 |
| Currax Pharmaceuticals LLC | 4 | $58 |
| Collegium Pharmaceutical, Inc. | 3 | $58 |
| Promius Pharma LLC | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Livanova USA, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Amylyx Pharmaceuticals, Inc. | 1 | $13 |
| Pernix Therapeutics Holdings, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$250,482
- UBRELVY$248,679
- QULIPTA$125,203
- AIMOVIG$124,551
- NURTEC ODT$78,565
- REYVOW$26,300
- AJOVY$18,517
- Trudhesa$16,952
- EMGALITY$14,950
- VYEPTI$4,104
- TRINTELLIX$1,265
- ZEMBRACE SYMTOUCH$140
- Symbravo$123
- ZAVZPRET$121
- Austedo XR$100
How this compares
$889,992 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 135 | $217,552 |
| UbrelvyUbrogepant | 80 | $105,310 |
| QuliptaAtogepant | 38 | $52,891 |
| Aimovig AutoinjectorErenumab-Aooe | 48 | $40,863 |
| Dihydroergotamine Mesylate | 22 | $26,748 |
| BotoxOnabotulinumtoxina | 21 | $25,956 |
| Emgality PenGalcanezumab-Gnlm | 27 | $19,990 |
| BelsomraSuvorexant | 18 | $9,882 |
| NeuproRotigotine | 11 | $9,219 |
| ReyvowLasmiditan Succinate | 13 | $9,188 |
| Zolmitriptan | 37 | $6,129 |
| Sumatriptan Succinate | 138 | $4,026 |
| Memantine Hcl ErMemantine Hcl | 42 | $3,738 |
| Duloxetine Hcl | 96 | $2,518 |
| Diphenhydramine Hcl | 46 | $2,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $636 | $217,552135 claims |
| AbbVieUbrelvy, Qulipta, Botox | $555,946 | $184,157139 claims |
| MerckBelsomra | $137 | $9,88218 claims |
| Lilly USA, LLCReyvow, Olanzapine | $74,726 | $9,45224 claims |
| Upsher-smith Laboratories LLCTopiramate | $125 | $41371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Rockford
- Andrea LawlessRockford$205K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.